Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $17.89, but opened at $16.83. Daiichi Sankyo shares last traded at $16.66, with a volume of 2,134 shares traded.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce”.
Read Our Latest Research Report on Daiichi Sankyo
Daiichi Sankyo Price Performance
The firm has a market capitalization of $30.37 billion, a P/E ratio of 18.95, a price-to-earnings-growth ratio of 1.90 and a beta of -0.11. The business has a 50-day moving average of $17.80 and a 200 day moving average of $17.72. The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, sell-side analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current fiscal year.
About Daiichi Sankyo
Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.
Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.
Featured Stories
- Five stocks we like better than Daiichi Sankyo
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
